TransMedics Group, Inc. (TMDX) FY2026 YTD Q2 P&L / Income Statement

TransMedics Group, Inc. (TMDX) FY2026 YTD Q2 P&L / Income Statement

Income statement for 2026-01-01 through 2026-06-30. View: Product and service. Revenue and costs use their disclosed categories.

Total revenue

363,881,000 US dollars

Total cost of revenue

149,522,000 US dollars

Gross profit

214,359,000 US dollars

Total operating expenses

177,326,000 US dollars

Income from operations

37,033,000 US dollars

Total other expense, net

negative 9,143,000 US dollars

Income before income taxes

27,890,000 US dollars

Provision for income taxes

5,893,000 US dollars

Net income

21,997,000 US dollars

Net product revenue revenue

219,130,000 US dollars

Service Revenue revenue

144,751,000 US dollars

Net product revenue cost of revenue

49,874,000 US dollars

Service Revenue cost of revenue

99,648,000 US dollars

Research, development and clinical trials

56,511,000 US dollars

Selling, general and administrative

120,815,000 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.